

SCOLR Pharma, Inc.
Form 8-K
March 16, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported):

March 11, 2010

SCOLR Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

001-31982
(Commission File No.)

19204 North Creek Parkway, Suite 100

91-1689591
(I.R.S. Employer

Identification No.)

Edgar Filing: SCOLR Pharma, Inc. - Form 8-K

Bothell, WA 98011

(Address of principal executive offices)

(425) 368-1050

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On March 11, 2010, SCOLR Pharma, Inc., a Delaware corporation (the Company) purchased from Advanced Healthcare Distributors, LLC, a New Hampshire limited liability company (ADC), all of ADC's right, title, and interest in and to the NUPRIN® trademark worldwide, excluding Canada. The Company paid \$180,000 in cash for these rights to the NUPRIN® trademark. On March 16, 2010 the Company issued a press release regarding this transaction, a copy of which is attached as exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	SCOLR Pharma, Inc. press release, dated March 16, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCOLR PHARMA, INC.

Dated: March 16, 2010

By: /s/ Richard M. Levy
Chief Financial Officer